Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.


The discovery of activating BRAF mutations in melanomas has led to the investigation of small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within the mitogen-activated protein kinase (MAPK) pathway. This article reviews the role of mutant BRAF in melanoma and summarizes the results of clinical trials evaluating inhibitors of… (More)
DOI: 10.1038/clpt.2013.197